Kura Oncology CEO buys 100,000 shares at $11.12

Kura Oncology, Inc. director and President and CEO Troy Edward Wilson reported a purchase of 100,000 shares of Common Stock on 2026-08-17 at a weighted average price of $11.12 per share, executed in multiple trades between $10.87 and $11.31.

Rhea-AI Filing Summary

Kura Oncology, Inc. director and President and CEO Troy Edward Wilson reported a purchase of 100,000 shares of Common Stock on 2026-08-17 at a weighted average price of $11.12 per share, executed in multiple trades between $10.87 and $11.31. The purchased shares are held indirectly by One Fish Two Fish Revocable Trust, bringing that trust’s reported holdings to 379,194 shares following the transaction. Additional reported positions include 300,000 shares held indirectly by Lorax Charitable Remainder Unitrust and 435,456 shares held directly by the reporting person.

Insider Trade Summary

Net Buyer: 100,000 shares

Net Buy 3 txns

Insider WILSON TROY EDWARD

Role President and CEO

Bought 100,000 shs ($1.11M)

Type	Security	Shares	Price	Value
Purchase	Common Stock F1	100,000	$11.12	$1.11M
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 379,194 shares (Indirect, by One Fish Two Fish Revocable Trust); Common Stock — 300,000 shares (Indirect, by Lorax Charitable Remainder Unitrust); Common Stock — 435,456 shares (Direct)

Footnotes (1)

1. F1. This transaction was executed in multiple trades at prices ranging from $10.87 to $11.31. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Key Figures

Shares purchased: 100,000 shares Weighted average purchase price: $11.12 per share Price range of trades: $10.87–$11.31 per share +3 more

6 metrics

Shares purchased 100,000 shares Common Stock purchased on 2026-08-17 in open market or private transactions

Weighted average purchase price $11.12 per share Weighted average price for the 100,000-share purchase, trades from $10.87 to $11.31

Price range of trades $10.87–$11.31 per share Range of prices for multiple trades comprising the reported 100,000-share purchase

Indirect holdings – One Fish Two Fish Revocable Trust 379,194 shares Total Kura Oncology common shares held indirectly by this trust after the purchase

Indirect holdings – Lorax Charitable Remainder Unitrust 300,000 shares Kura Oncology common shares held indirectly by Lorax Charitable Remainder Unitrust

Direct holdings 435,456 shares Kura Oncology common shares held directly by Troy Wilson as reported

Key Terms

weighted average purchase price, revocable trust, Charitable Remainder Unitrust

3 terms

weighted average purchase price financial

"The price reported above reflects the weighted average purchase price."

The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.

revocable trust financial

"direct_or_indirect: I, nature_of_ownership: by One Fish Two Fish Revocable Trust"

A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.

Charitable Remainder Unitrust financial

"nature_of_ownership: by Lorax Charitable Remainder Unitrust"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did KURA CEO Troy Wilson report on this Form 4?

Troy Wilson reported a purchase of 100,000 Kura Oncology (KURA) common shares on 2026-08-17 at a weighted average price of $11.12 per share, executed in multiple trades between $10.87 and $11.31.

At what prices did Troy Wilson buy Kura Oncology (KURA) shares on 2026-08-17?

The reported purchase was executed in multiple trades at prices ranging from $10.87 to $11.31 per share, with a disclosed weighted average purchase price of $11.12 per share for the 100,000 KURA shares acquired.

How many Kura Oncology (KURA) shares does the One Fish Two Fish Revocable Trust hold after the transaction?

Following the reported purchase, the One Fish Two Fish Revocable Trust holds 379,194 Kura Oncology common shares indirectly attributable to Troy Wilson, including the newly acquired 100,000 shares bought on 2026-08-17.

What are Troy Wilson’s other reported indirect Kura Oncology (KURA) holdings?

In addition to the One Fish Two Fish Revocable Trust, Troy Wilson reports 300,000 KURA shares held indirectly by Lorax Charitable Remainder Unitrust, as of the same reporting date, separate from his direct share ownership.

How many Kura Oncology (KURA) shares does Troy Wilson hold directly after this Form 4?

The filing reports that Troy Wilson holds 435,456 Kura Oncology common shares directly, in addition to his indirect holdings through the One Fish Two Fish Revocable Trust and the Lorax Charitable Remainder Unitrust.

Was Troy Wilson’s Kura Oncology (KURA) stock purchase under a Rule 10b5-1 plan?

The Form 4 indicates the Rule 10b5-1 checkbox is not marked as affirming a trading plan, and the footnote does not reference any such plan for the 100,000-share KURA purchase.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/17/2026 - 04:46 PM Accepted by SEC EDGAR 08/17/2026 - 04:45 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WILSON TROY EDWARD

(Last) (First) (Middle)

C/O KURA ONCOLOGY, INC.

4930 DIRECTORS PLACE, SUITE 500

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/17/2026		P		100,000	A	$11.12(1)	379,194	I	by One Fish Two Fish Revocable Trust
Common Stock								300,000	I	by Lorax Charitable Remainder Unitrust
Common Stock								435,456	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $10.87 to $11.31. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

	Teresa Bair, Attorney-in-fact for Troy E. Wilson	08/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)